Table 2.
Hazard ratios (HR) and 95% confidence intervals (CI) of prognostic factors in patients with invasive breast cancer by univariate and multivariate Cox regression analysis
| Univariate analysis | Multivariate analysis | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| With adjustment on TNM stage | Without adjustment on TNM stage | ||||||||
| HR | 95% CI | p | HR | 95% CI | p | HR | 95% CI | p | |
| Mode of detection | < 0.001 | 0.325 | < 0.001 | ||||||
| NSP group | 1 | 1 | 1 | ||||||
| SP group | 0.25 | 0.17–0.37 | 0.75 | 0.48–1.15 | 0.28 | 0.19–0.42 | |||
| IC group | 0.51 | 0.29–0.87 | 0.74 | 0.42–1.30 | 0.48 | 0.28–0.83 | |||
| Age | 0.128 | 0.003 | 0.05 | ||||||
| > 65 years | 1 | 1 | 1 | ||||||
| ≤ 65 years | 0.77 | 0.54–1.08 | 0.58 | 0.41–0.84 | 0.70 | 0.49–0.99 | |||
| TNM stage | < 0.001 | < 0.001 | – | ||||||
| I | 1 | 1 | – | ||||||
| II | 2.62 | 1.40–4.90 | 2.59 | 1.33–5.02 | – | – | |||
| III | 14.48 | 8.03–26.09 | 13.25 | 7.02–25.01 | – | – | |||
| IV | 76.92 | 44.12–134.08 | 63.69 | 33.69–120.39 | – | – | |||
| SBR grade | < 0.001 | – | – | ||||||
| 1 | 1 | – | – | ||||||
| 2 | 3.02 | 1.56–5.84 | – | – | – | – | |||
| 3 | 5.82 | 2.93–11.59 | – | – | – | – | |||
| Hormonal receptor status | < 0.001 | < 0.001 | < 0.001 | ||||||
| OR+/PR+ | 1 | 1 | 1 | ||||||
| OR+/PR- or OR-/PR+ | 2.78 | 1.82–4.25 | 1.97 | 1.28–3.02 | 2.49 | 1.63–3.81 | |||
| OR-/PR- | 4.30 | 2.87–6.45 | 2.88 | 1.89–4.38 | 3.89 | 2.58–5.87 | |||
| Her-2 receptor status | 0.050 | – | – | ||||||
| Positive | 1 | – | – | ||||||
| Negative | 0.63 | 0.40–1.00 | – | – | – | – | |||
| Type of treatment | < 0.001 | – | – | ||||||
| Surgery ± RT | 1 | – | – | ||||||
| Surgery + CT ± RT | 3.75 | 2.18–6.45 | – | – | – | – | |||
| Neoadjuvant treatment + Surgery ± RT/CT | 11.36 | 6.33–20.39 | – | – | – | – | |||
| Absence of surgery | 84.72 | 48.26–148.73 | – | – | – | – | |||
SP group, patients detected by the screening programme; IC group, patients with interval cancer; NSP group, patients detected without participating in the screening programme; SBR, Scarff-Bloom-Richardson grade; OR, oestrogen receptor; PR, progesterone receptor; RT, adjuvant radiotherapy; CT, adjuvant chemotherapy